TNB Financial reduced its position in Aetna Inc. (NYSE:AET) by 5.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,317 shares of the company’s stock after selling 263 shares during the period. TNB Financial’s holdings in Aetna were worth $655,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Ibex Wealth Advisors increased its stake in Aetna by 3.5% in the fourth quarter. Ibex Wealth Advisors now owns 15,651 shares of the company’s stock worth $1,918,000 after buying an additional 526 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Aetna by 31.6% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 52,641 shares of the company’s stock worth $6,713,000 after buying an additional 12,648 shares during the last quarter. Columbus Circle Investors increased its stake in Aetna by 358.8% in the first quarter. Columbus Circle Investors now owns 51,831 shares of the company’s stock worth $6,611,000 after buying an additional 40,535 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Aetna by 0.3% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 282,165 shares of the company’s stock worth $35,990,000 after buying an additional 875 shares during the last quarter. Finally, Toronto Dominion Bank increased its stake in Aetna by 57.0% in the first quarter. Toronto Dominion Bank now owns 95,608 shares of the company’s stock worth $12,194,000 after buying an additional 34,719 shares during the last quarter. Institutional investors and hedge funds own 91.73% of the company’s stock.
Aetna Inc. (NYSE AET) opened at 152.15 on Friday. Aetna Inc. has a 1-year low of $104.59 and a 1-year high of $161.69. The firm has a market capitalization of $50.53 billion, a P/E ratio of 33.77 and a beta of 0.54. The stock’s 50 day moving average is $154.26 and its 200-day moving average is $139.02.
Aetna (NYSE:AET) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $3.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.34 by $1.08. Aetna had a net margin of 2.52% and a return on equity of 20.52%. The company had revenue of $15.52 billion for the quarter, compared to the consensus estimate of $15.34 billion. During the same period in the prior year, the firm posted $2.21 EPS. Aetna’s revenue for the quarter was down 2.7% on a year-over-year basis. Analysts forecast that Aetna Inc. will post $9.52 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, July 28th. Investors of record on Thursday, July 13th were given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.31%. The ex-dividend date of this dividend was Tuesday, July 11th. Aetna’s dividend payout ratio (DPR) is 43.67%.
TRADEMARK VIOLATION WARNING: “Aetna Inc. (NYSE:AET) Position Decreased by TNB Financial” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/08/12/aetna-inc-nyseaet-stake-cut-by-tnb-financial-updated-updated-updated.html.
A number of equities research analysts have weighed in on AET shares. Citigroup Inc. started coverage on Aetna in a report on Wednesday, June 28th. They set a “buy” rating and a $180.00 price objective on the stock. Cleveland Research raised Aetna from a “neutral” rating to a “buy” rating in a report on Thursday, May 11th. Cantor Fitzgerald reiterated a “buy” rating and issued a $150.00 target price on shares of Aetna in a research note on Friday, May 12th. Credit Suisse Group reiterated a “buy” rating and issued a $155.00 target price on shares of Aetna in a research note on Wednesday, May 17th. Finally, Barclays PLC reiterated an “overweight” rating and issued a $162.00 target price on shares of Aetna in a research note on Monday, May 15th. Eight analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $157.09.
In related news, EVP Margaret M. Mccarthy sold 27,028 shares of the stock in a transaction dated Wednesday, June 7th. The shares were sold at an average price of $149.23, for a total transaction of $4,033,388.44. Following the sale, the executive vice president now directly owns 33,563 shares of the company’s stock, valued at approximately $5,008,606.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Mark T. Bertolini sold 103,547 shares of the stock in a transaction dated Wednesday, May 17th. The shares were sold at an average price of $140.79, for a total transaction of $14,578,382.13. Following the sale, the chairman now directly owns 659,888 shares in the company, valued at $92,905,631.52. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.
Aetna Inc is a diversified healthcare benefits company. The Company operates through three segments: Health Care, Group Insurance and Large Case Pensions. It offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid healthcare management services, Medicare Advantage and Medicare Supplement plans, workers’ compensation administrative services and health information technology (HIT) products and services.
What are top analysts saying about Aetna Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aetna Inc. and related companies.